AveXis, Inc. (AVXS) saw its loss widen to $29.72 million, or $1.07 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $20.84 million, or $1.24 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $29.96 million, compared with an operating loss of $20.89 million in the previous year period.
"We are very pleased with our progress during the first quarter and recent weeks, including the recently reported encouraging results from the closeout of the Phase 1 trial of AVXS-101 in SMA Type 1," said Sean Nolan, President and Chief Executive Officer of AveXis. "Our team is focused on executing our plan to bring AVXS-101 to patients suffering from SMA Type 1 as quickly and safely as possible."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
